Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
information fournie par Boursorama CP 07/11/2024 à 17:45
Ajoutez Boursorama à vos sources préférées

Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant standard of care remain disease-free


TG4050 induced specific and sustained immune responses. A Phase II part is now enrolling patients internationally to build on this promising outcome


Strasbourg, France & Tokyo, Japan, November 7, 2024, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies, today announced 24.1-month median follow-up data from the ongoing randomized Phase I trial of TG4050 in the adjuvant treatment of head and neck cancers. The data will be presented in a poster at the Society for ImmunoTherapy of Cancer (SITC) 2024 Annual Meeting on November 9 in Houston, TX.


.../...

Valeurs associées

TRANSGENE
0,7240 EUR Euronext Paris +0,14%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
Pétrole Brent
98,4 -2,61%
CAC 40
8 372,28 +0,88%
TOTALENERGIES
75,9 -0,37%
Or
4 055,93 0,00%
2CRSI
27,58 +4,08%
Chargement...

Pages les plus populaires

L'offre BoursoBank